Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-07-25

Clinical Trial Update: AZD6765 Severe Major Depressive Disorder (MDD) IV [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for AZD6765 in adults with Major Depressive Disorder, which has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AZD6765 (lanicemine)

Snippet

Sponsor: AstraZeneca | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED